Professional Documents
Culture Documents
discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/291845196
CITATION
READS
105
2 authors, including:
Mazhar Iqbal
National Institute for Biotechnology and Ge
58 PUBLICATIONS 349 CITATIONS
SEE PROFILE
REVIEW
Abstract
WJG|www.wjgnet.com
1684
INTRODUCTION
Infection with hepatitis C virus (HCV) is a major global
health concern. With an estimated 170 million people
infected with HCV worldwide, this disease is proving
to be an escalating economic, social and health
[1,2]
burden . Although the prevalence of HCV infection
seems to have declined in the past two decades in the
[3,4]
[5,6]
United States , western and northern Europe ,
[7]
[8]
Japan and Australia , the burden of this disease in
many of the lesser developed and developing countries
[2]
is continuously on the rise . Awareness, improved
safety of blood products, the availability of affordable
and effective HCV therapies have contributed significantly
to the decline in HCV in developed countries. However,
lack of awareness, inadequate blood screening facilities,
nosocomial transmission and a lack of effective treatments
(due to various reasons) have so far been the major
factors responsible for seemingly inexorable rise in
[2,9]
HCV infection in many developing countries .
HCV is a member of the family Flaviviridae with
an approximately 9.6 kb single-stranded, positive
[10]
sense RNA genome . Owing to the poor fidelity
of HCV RNA-dependent-RNA-polymerase (NS5B
protein), the virus exhibits a high level of sequence
[10]
heterogeneity . Based on sequence homology six
major HCV genotypes (1-6) and numerous distinct
subtypes (denoted by a small English alphabet suffixed
after genotype, e.g., 1b, 3a etc.) have so far been
[11]
identified . The distribution of HCV genotypes is
highly variable. Genotypes 1-3 are distributed globally,
whereas genotypes 4 and 5 are restricted to the Middle
East and Africa, and genotype 6 occurs predominantly
[2,12-14]
in south-east Asian countries
. HCV genotype
[1]
3 is endemic on the Indian subcontinent . Multiple
studies have identified subtype 3a as the most
[15,16]
prevalent HCV variant in Pakistan
. However,
WJG|www.wjgnet.com
1685
Analysis
Methodology
Literature search
WJG|www.wjgnet.com
1686
0-2
2.1-5
5.1-10
Above 10
Not available
WJG|www.wjgnet.com
1687
Place
Method
Sample size
Male
1
2
3
4
5
6
2009
2009
2010
2010
2010
2010
7
8
2010
2010
Lahore
Larkana
Swat
Mansehra
Thatta/Nausheroferoz
Karachi
(peri-Urban)
Karachi
9
10
11
2010
2010
2010
Multan
Lahore
Faisalabad
Gujranwala
Gujrat
Sargodha
Rawalpindi
Sialkot
Bahawalpur
Islamabad
Mansehra
National Survey
12
13
14
15
16
17
2011
2011
2012
2012
2014
2014
Gujranwala
Karachi
Kech
Punjab
Mardan
Peshawar
Seroprevalence (%)
Ref.
Female
Total
Male
Female
Total
4.12
11.3
26
6.5
6.66
8.81
7.0
25.1
23.83
[38]
[46]
[45]
[36]
[29]
[28]
3.17
[34]
[41]
ELISA9
ICT1
ICT2
ICT2
ICT3
EIA4
353
290
649
97
300
1348
2000
450
590
400
303
1997
7.37
6.2
19
ICT9
ELISA9
351
153
504
2.8
ICT9
ICT9
ICT3
625
1892
2736
16522
9770
1620
445
24707
363
394
24444
252
254
22599
625
1892
2736
16522
9770
1620
445
24707
363
252
648
47043
9.6
9.4
8.8
7.3
6.8
6.7
6.7
6.2
5.0
11.8
4.9
EIA5
CLIA6
EIA7
EIA7
ICT8
CMIA4
1770
709
14027
757
543
732
1291
14027
662
439
2502
32049
2000
1419
982
2.6
7.62
3.13
13.6
15.4
5.23
24.6
9.4
4.8
1.68
4.34
9.52
9.7
9.6
9.4
8.8
7.3
6.8
6.7
6.7
6.2
5.0
24.6
10.34
4.87
[40]
[44]
[21]
2.32
9.75
5.5
3.13
11.7
12.93
[43]
[35]
[26]
[39]
[37]
[42]
Nobis Labordiagnostica, Cluj-Napoca, Romania; 2Acon Laboratories, CA, United States; 3Bionike Inc. CA, United States; 4Abbott Diagnostics, IL, United
States; 5DSI, srl. Saronno VA, Italy; 6Roche Diagnostics, CA, United States; 7DiaSorin International Inc., Saluggia, Italy; 8Accurate Diagnostic
Labs, NJ, United States; 9Manufacturer not mentioned in cited reference. ELISA: enzyme linked immunosorbent assay; CLIA: Chemiluminescence
immunoassay; ICT: Immunochromatographic test; EIA: Enzyme immunoassay; CMIA: Chemiluminescent microparticle immunoassay.
[81]
WJG|www.wjgnet.com
1688
Year
Place
Method
Sample size
Seroprevalence (%)
Ref.
1
2
3
4
5
6
7
8
9
10
11
12
13
2009
2010
2010
2011
2011
2011
2012
2012
2012
2013
2013
2013
2014
Mirpurkhas
Multan
Peshawar
KPK/FATA
KPK/FATA
Karachi
Karachi
Peshawar
Sargodha
Karachi
Quetta
Lahore
Karachi
ELISA7
ELISA1
ELISA7
ELISA2
ELISA2
-8
ELISA3
ELISA2
ELISA3
MEIA/CLIA4
ELISA2
ELISA5
CLIA6
804
10000
32042
7148
62251
5717
5517
127828
100
108598
356
245
42830
15.05
4.90
1.57
1.89
2.60
1.90
2.00
2.46
12.00
2.61
20.8
15.00
1.65
[25]
[88]
[92]
[89]
[91]
[86]
[83]
[84]
[85]
[87]
[27]
[82]
[90]
Labkit Chemelex, Barcelona, Spain; 2Biokit; 3General Biologicals Corporation, Taiwan; 4Abbott Diagnostics, 5DiaSorin; 6Ortho Clinical Diagnostics, NJ,
United States; 7Manufacturer not mentioned in cited reference; 8Method not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; FATA: Federally
Administered Tribal Areas; ELISA: enzyme linked immunosorbent assay; MEIA: Microparticle immunoassay; CLIA: Chemiluminescence immunoassay.
Year
Place
Hepatocellular carcinoma
1
2009
Punjab/KPK
2
2009
Pakistan
3
2010
Karachi
4
2013
Pakistan
5
2014
Hyderabad
Liver disease
6
2009
Swat
7
2009
Pakistan
8
2010
Karachi
Hepatic encephalopathy
9
2009
Hyderabad
Suspected for viral hepatitis
10
2014
Islamabad
Method
Sample size
Seroprevalence (%)
Ref
ELISA1
EIA2
-5
ELISA4
ELISA4
145
82
40
645
188
76.5
79.2
50
48.5
66
[97]
[98]
[94]
[95]
[96]
ELISA4
EIA2
-5
110
107
5153
AH
7
CH/CLD
62.6
72.9
Carrier
51.7
Cirrhosis
63.6
24.3
59.4
[99]
[98]
[94]
-5
87
66.67
[100]
ELISA3
845
24.8
[101]
DRG Instruments, Germany; 2Abbott Diagnostics; 3Biokit; 4Manufacturer not mentioned in cited reference; 5Method not mentioned in cited reference. AH:
Acute hepatitis; CH: Chronic hepatitis; CLD: Chronic liver disease; ELISA: enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; KPK: Khyber
Pakhtunkhwa.
[93]
WJG|www.wjgnet.com
1689
Year
Place
Pregnant women
1
2009
Hazara
2
2009
Swat
3
2009
Karachi
4
2010
Multan
5
2011
Karachi
6
2013
Hyderabad
Multi-transfused population (including pediatric population)
7
2009
Islamabad
8
2010
Lahore
9
2011
KPK
10
2011
Karachi
11
2012
Karachi
12
2014
Rawalpindi
Intravenous drug users
13
2011
KPK
14
2011
KPK
Peshawar
Kohat
Mardan
Method
Sample size
ELISA1
ICT6
EIA2
ICT6
ELISA3
ELISA2
500
5607
5902
500
18000
3078
Seroprevalence (%)
8.6
2.6
1.8
7.0
5.79
4.7
Ref.
[104]
[105]
[106]
[107]
[102]
[103]
ELISA6
Questionnaire
ICT4
ELISA3
ELISA5
ELISA6
103
408
40
173
160
95
36.0
1.5
15.0
51.4
13.0
49.5
[108]
[110]
[111]
[86]
[83]
[109]
ICT4
ICT4
42
14.28
[111]
[113]
100
60
40
35.0
25.0
32.5
Ortho Clinical Diagnostics; 2Abbott Diagnostics; 3DiaSorin; 4Acon Laboratories, CA, United States; 5General Biologicals Corporation; 6Manufacturer
not mentioned in cited reference. KPK: Khyber Pakhtunkhwa; ELISA: enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; ICT:
Immunochromatographic test.
[1]
Multi-transfused individuals
WJG|www.wjgnet.com
1690
Year
Place
Method
Sample Size
Seroprevalence (%)
Ref.
2008
2011
Abbottabad
Peshawar
ELISA7
ICT1
125
824
5.6
4.1
[116]
[115]
2010
2010
Sindh
Karachi
ELISA2
ELISA3
7539
357
12.8
15.2
[117]
[118]
2011
2011
KPK
Peshawar
ICT4
ELISA1
25
384
28.0
29.2
[111]
[119]
2010
Sindh
ELISA5
396
23.5
[120]
2011
Karachi
ELISA6
129
3.9
[102]
Acurate Diagnostics; 2Medical Biological Services, Italy; 3Abbott Diagnostics; 4Acon Laboratories; 5Biokit; 6DiaSorin; 7Manufacturer not mentioned in cited
reference. KPK: Khyber Pakhtunkhwa; ELISA: enzyme linked immunosorbent assay; ICT: Immunochromatographic test.
1
[125]
WJG|www.wjgnet.com
1691
Year
Place
Method
2010
Lahore
ELISA4
2009
Karachi
2010
2011
2013
Seroprevalence (%)
Ref.
558
13.4
[130]
EIA1
548
16.2
[106]
Sukkur
KPK
Kharian
ICT5
ICT2
ELISA5
913
25
554
13.8
8.0
6.4
[126]
[111]
[122]
2011
KPK
ICT2
35
14.28
[111]
2010
Multan
ELISA3
3000
30.2
[88]
2012
Karachi
ELISA5
377
11.4
[127]
2012
Karachi/
Rawalpindi
ELISA5
355
9.01
[128]
ELISA4
110
9.1
[121]
ELISA1
39780
21.99
[124]
ELISA5
ELISA1
ELISA5
25944
2965
9564
3.3
12.8
6.38
[125]
[123]
[129]
Tuberculosis patients
10
2013
Rahim Yar Khan
Sexually transmitted infection patients
11
2014
Faisalabad
Seeking hospital care (Misc diseases/disease not defined)
12
2010
Bannu
13
2011
Karachi
14
2011
Kotli (AJK)
Sample size
Abbott Diagnostics; 2Acon Laboratories; 3Labkit; 4Bio-tech Company Limited, United States; 5Manufacturer not mentioned in cited reference. KPK: Khyber
Pakhtunkhwa; ELISA: enzyme linked immunosorbent assay; EIA: Enzyme immunoassay; ICT: Immunochromatographic test.
[111,119]
WJG|www.wjgnet.com
1692
Year
General population
1
2
3
2010
2010
2012
4
2013
5
2014
Intravenous drug users
6
2011
7
2011
Dialysis patients
8
2011
9
2011
Blood donors
10
2011
Health care workers
11
2011
Multi transfused population
12
2011
Patients undergoing major surgery
13
2011
Dental surgery patients
14
2011
Pregnant women
15
2011
Place
Swat
Mansehra
Rawalpindi
Islamabad
Lahore
Mardan
Sample size
Ref.
Male
Female
Total
Male
Female
Total
290
300
147
75
1914
757
300
100
156
125
2332
662
590
400
303
200
4246
1419
2.8
4.0
17.7
5.3
5.3
11.5
5.7
2.0
16.7
3.2
4.7
5.1
4.2
3.5
17.2
4.0
4.9
8.5
[45]
[36]
[135]
[134]
[37]
KPK
KPK
42
200
14.3
24.0
[111]
[113]
KPK
KPK
25
384
28.0
27.6
[111]
[119]
1.6
[89]
KPK/FATA
7148
KPK
824
2.8
[115]
KPK
40
15.0
[111]
KPK
25
8.0
[111]
KPK
35
14.3
[111]
-1
[102]
Karachi
18000
Out of 18000 subjects studied, 1043 women tested positive for anti- hepatitis C virus (HCV) during screening; only 640 out of these 1043 agreed to undergo
nucleic acid testing of which 510 tested positive for HCV-RNA. KPK: Khyber Pakhtunkhwa; FATA: Federally Administered Tribal Areas.
WJG|www.wjgnet.com
1693
Ref.
3
Mixed
Untypable
12.1
27.88
37.8
17
14.29
2.4
8.9
16.4
10.8
1.8
17.4
6.4
21
2.2
5.7
15.1
17.8
2.5
4.3
18.8
7.7
32.1
15.6
1a
1b
2a
2b
3a
3b
4a
4b
5a
6a
3.5
6.1
0.72
5.4
1.5
7.14
12.1
14.3
6.8
5.6
2.6
12.5
7.4
10
1.3
1
8.8
5.3
2.9
3.3
23.6
4.3
0.9
7.1
0.5
0.8
6
0.72
1
15.1
6.1
88.1
42.3
80.26
34.1
31
28.6
64.5
32.1
54.4
90.3
82.6
42.9
26.4
56.4
82.1
38.2
45.5
39.4
70.3
61
55.9
73.9
66.1
86.8
50
68.3
3
12.1
6
7
8
3.6
6.73
7.6
6.4
17.8
8.2
0.6
0.2
22.3
16.5
15
13.9
21
16
6.3
5.5
8.9
3.2
13
2.6
2.2
10.7
2.6
0.0011
6.7
1.8
0.6
14.29
-
0.5
0.4
0.6
-
0.1
3.2
10.7
8.2
2.8
2.4
0.241
-
0.8
2.4
12.5
-
2.5
1.4
-
0.5
-
2
0.1
-
1.2
-
2.4
0.1
-
2.5
1.2
3.6
4.6
0.8
8.9
5.8
3.6
0.7
3
5.1
1.5
0.8
0.9
1.5
11
0.21
-
8.1
39
35.71
1.2
8.9
1.3
0.3
9.8
13.2
12
6.5
24.9
2.1
7.4
1.1
10.3
1
0.4
1.8
0.31
-
0.2
1.8
6.6
1
6.1
0.2
0.9
2.2
1.2
1.2
0.021
-
0.9
-
4.1
7.1
2
7.3
16
2.6
4.7
1.2
4.3
2.2
-
[142]
[45]
[151]
[154]
[17]
[113]
[156]
[119]
[152]
[141]
[150]
[149]
[37]
[143]
[146]
[148]
[145]
[18]
[157]
[153]
[155]
[115]
[144]
[149]
[140]
[158]
WJG|www.wjgnet.com
CONCLUSION
HCV prevalence data published recently (2009/10
to 2015) suggests that HCV infection is on the
rise in Pakistan. While the almost 40% increase in
HCV seroprevalence among the general population
suggested by the analysis here, compared to
previous estimates (6.8% rather than 4.7%-5%)
is alarming, high prevalence rates among persons
who have had surgical and medical interventions
suggest a predominant involvement of nosocomial
transmission in the spread of HCV in Pakistan. Given
the evidence of high nosocomial transmission as
well as increased burden of this disease in lesser
developed areas (discussed below) where health
service related malpractices are more common, there
is an urgent need to implement strict measures in
order to ensure safe medical practices. Reducing
unnecessary injections, ensuring that surgical and
dental instruments are sterilized or disposable
instruments are used, avoiding shared razors at barber
shops as well as unhygienic piercing and tattooing
instruments are among the most important preventive
measures. Although the response rate to conventional
IFN-ribavirin therapy regimen among genotype 3a
patients (the most prevalent genotype in Pakistan) is
1694
Genotype 1
Genotype 2
Genotype 3
Genotype 4
60
Genotype 5
Genotype 6
Mixed genotype
40
Untypable
20
an
Ba
lo
c
hi
st
KP
K
Pu
nj
a
Si
nd
Figure 2 Distribution pattern of major hepatitis C virus genotypes at the province level. KPK: Khyber Pakhtunkhwa.
6a
5a
1
6
1
4b
1
1b
Mixed
genotype
1a
Untypable
1c
2a
2
2b
2c
4a
4
3c
3b
3a
Figure 3 Relative frequency distribution of hepatitis C virus subtypes in Pakistan. 1Undefined subtype.
WJG|www.wjgnet.com
ACKNOWLEDGMENTS
The authors are grateful to Professor Rob W Briddon
for critically reviewing this manuscript. We are also
thankful to Mr. Tahir Mehdi and Mr Shoaib Tariq for
their help in producing the map of HCV prevalence.
1695
REFERENCES
1
2
3
5
6
7
8
9
10
11
12
13
14
15
16
17
18
WJG|www.wjgnet.com
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
1696
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
WJG|www.wjgnet.com
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
1697
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
WJG|www.wjgnet.com
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
1698
10.1002/ijc.25516]
Ahmed W, Qureshi H, Arif A, Alam SE. Changing trend of
viral hepatitis--A twenty one year report from Pakistan Medical
Research Council Research Centre, Jinnah Postgraduate Medical
Centre, Karachi. J Pak Med Assoc 2010; 60: 86-89 [PMID:
20209690]
Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA,
Farooq O, Ahmed B, Ul Haq T, Jafri W. Hepatocellular carcinoma
in Native South Asian Pakistani population; trends, clinicopathological characteristics & differences in viral marker negative
& viral-hepatocellular carcinoma. BMC Res Notes 2013; 6: 137
[PMID: 23566475 DOI: 10.1186/1756-0500-6-137]
Munaf A, Memon MS, Kumar P, Ahmed S, Kumar MB.
Comparison of viral hepatitis-associated hepatocellular carcinoma
due to HBV and HCV - cohort from liver clinics in Pakistan. Asian
Pac J Cancer Prev 2014; 15: 7563-7567 [PMID: 25292029 DOI:
10.7314/APJCP.2014.15.18.7563]
Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S,
Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin
S. Hepatitis C virus genotype 3a infection and hepatocellular
carcinoma: Pakistan experience. World J Gastroenterol 2009; 15:
5080-5085 [PMID: 19860002 DOI: 10.3748/wjg.15.5080]
Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U,
Hamid S, Jafri W, Mizokami M. Epidemic spread of hepatitis C
virus genotype 3a and relation to high incidence of hepatocellular
carcinoma in Pakistan. J Med Virol 2009; 81: 1189-1197 [PMID:
19475617 DOI: 10.1002/jmv.21466]
Khan P, Ahmad A, Muhammad N, Khan TM, Ahmad B. Screening
of 110 cirrhotic patients for hepatitis B and C at Saidu Teaching
Hospital Saidu Sharif Swat. J Ayub Med Coll Abbottabad 2009; 21:
119-121 [PMID: 20364758]
Devrajani BR, Shah SZ, Devrajani T, Kumar D. Precipitating
factors of hepatic encephalopathy at a tertiary care hospital
Jamshoro, Hyderabad. J Pak Med Assoc 2009; 59: 683-686 [PMID:
19813682]
Khan J, Shafiq M, Mushtaq S, Ayaz S, Ullah R, AbdEI-Salam NM,
Fouad H, Wasim MA. Seropositivity and coinfection of hepatitis B
and C among patients seeking hospital care in Islamabad, Pakistan.
Biomed Res Int 2014; 2014: 516859 [PMID: 25050357 DOI:
10.1155/2014/516859]
Aziz S, Hossain N, Karim SA, Rajper J, Soomro N, Noorulain W,
Qamar R, Khanani R. Vertical transmission of hepatitis C virus
in low to middle socio-economic pregnant population of Karachi.
Hepatol Int 2011; 5: 677-680 [PMID: 21484109 DOI: 10.1007/
s12072-010-9229-8]
Bibi S, Dars S, Ashfaq S, Ara Qazi R, Akhund S. Seroprevalence
and risk factors for hepatitis C virus (HCV) infection in pregnant
women attending public sector tertiary care hospital in Hyderabad
Sindh. Pak J Med Sci 2013; 29: 505-508 [PMID: 24353565]
Gul N, Sarwar J, Idris M, Farid J, Rizvi F, Suleman M, Shah
SH. Seroprevalence of hepatitis C in pregnant females of Hazara
division. J Ayub Med Coll Abbottabad 2009; 21: 83-86 [PMID:
21067033]
Khattak ST, Ali Marwat M, Khattak Iu, Khan TM, Naheed T.
Comparison of frequency of hepatitis B and hepatitis C in pregnant
women in urban and rural area of district Swat. J Ayub Med Coll
Abbottabad 2009; 21: 12-15 [PMID: 20524459]
Sami S, Korejo R, Bhutta SZ. Prevalence of hepatitis B and
C: a Jinnah Postgraduate Medical Centre experience. J Obstet
Gynaecol Res 2009; 35: 533-538 [PMID: 19527395 DOI: 10.1111/
j.1447-0756.2008.00991.x]
Taseer IU, Ishaq F, Hussain L, Safdar S, Mirbahar AM, Faiz SA.
Frequency of anti-HCV, HBsAg and related risk factors in pregnant
women at Nishtar Hospital, Multan. J Ayub Med Coll Abbottabad
2010; 22: 13-16 [PMID: 21409894]
Asif N, Zafar T, Hassan K, Naseem L. Seroprevalence Anti HCV
Antibodies, HCV-RNA and its Genotypes among Patients of
Hemophilia, at Hemophilia Treatment Centre Pakistan Institute of
Medical Sciences, Islamabad. Int J Pathol 2009; 7: 84-87
Din G, Malik S, Ali I, Ahmed S, Dasti JI. Prevalence of hepatitis
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
WJG|www.wjgnet.com
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
1699
WJG|www.wjgnet.com
1700